<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choudhry, N. K.</style></author><author><style face="normal" font="default" size="100%">Patrick, A. R.</style></author><author><style face="normal" font="default" size="100%">Glynn, R. J.</style></author><author><style face="normal" font="default" size="100%">Avorn, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels</style></title><secondary-title><style face="normal" font="default" size="100%">J Am Coll Cardiol</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Feb 15</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/21310313</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">2011/02/12</style></edition><volume><style face="normal" font="default" size="100%">57</style></volume><pages><style face="normal" font="default" size="100%">784-91</style></pages><isbn><style face="normal" font="default" size="100%">1558-3597 (Electronic)0735-1097 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">OBJECTIVES: We sought to evaluate the cost-effectiveness of applying the JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial results into clinical practice. BACKGROUND: The JUPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein (LDL) cholesterol levels. The implications of expanding treatment recommendations based on these results have not been evaluated. METHODS: We constructed a cost-effectiveness model of men &gt;/=50 years and women &gt;/=60 years with LDL cholesterol levels of &lt;130 mg/dl and no known cardiovascular disease. We compared: 1) hs-CRP testing followed by rosuvastatin treatment for patients with hs-CRP levels &gt;/=2.0 mg/l; and 2) usual care (i.e., no testing and no treatment). Estimates of treatment effectiveness were based on the JUPITER trial and were varied in sensitivity analyses. RESULTS: Among patients with LDL &lt;130 mg/dl and hs-CRP levels &gt;/=2.0 mg/l, rosuvastatin had an incremental cost-effectiveness of $25,198 per quality-adjusted life year (QALY) gained compared to usual care. If the effectiveness of rosuvastatin were 50% of that observed in JUPITER, the incremental cost-effectiveness ratio would increase to $50,871 per QALY. Implementing this strategy only in patients with a Framingham risk score &gt;/=10% yielded an incremental cost-effectiveness of $14,205 per QALY. Among such intermediate-risk patients, a JUPITER-based strategy becomes cost-saving at a rosuvastatin price of &lt;$0.86 per day. CONCLUSIONS: Rosuvastatin treatment for JUPITER-eligible patients appears to be cost-effective, particularly among those with a Framingham risk score &gt;/=10%.</style></abstract><accession-num><style face="normal" font="default" size="100%">21310313</style></accession-num><notes><style face="normal" font="default" size="100%">Choudhry, Niteesh KPatrick, Amanda RGlynn, Robert JAvorn, JerryUnited StatesJournal of the American College of CardiologyJ Am Coll Cardiol. 2011 Feb 15;57(7):784-91.</style></notes><auth-address><style face="normal" font="default" size="100%">Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</style></auth-address></record></records></xml>